[HTML] nih.gov

[HTML][HTML] The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the …

Y Zhang, V Akhil, HS Seo, HR Park, SH Kim, SH You… - Theranostics, 2024 - ncbi.nlm.nih.gov
Radiotherapy (RT) triggers immunogenic cell death (ICD). L-ASNase, which catalyzes the
conversion of asparagine (Asn), thereby depleting it, is used in the treatment of blood …
被引用次数：3 相关文章

The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor …

Y Zhang, V Akhil, HS Seo, HR Park, SH Kim… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Radiotherapy (RT) triggers immunogenic cell death (ICD). L-ASNase, which catalyzes the
conversion of asparagine (Asn), thereby depleting it, is used in the treatment of blood …

The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor …

Y Zhang, V Akhil, HS Seo, HR Park, SH Kim, SH You… - Theranostics, 2024 - europepmc.org
Radiotherapy (RT) triggers immunogenic cell death (ICD). L-ASNase, which catalyzes the
conversion of asparagine (Asn), thereby depleting it, is used in the treatment of blood …

The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor …

Y Zhang, V Akhil, HS Seo, HR Park, SH Kim, SH You… - Theranostics, 2024 - europepmc.org
Radiotherapy (RT) triggers immunogenic cell death (ICD). L-ASNase, which catalyzes the
conversion of asparagine (Asn), thereby depleting it, is used in the treatment of blood …